Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Michael K. Farris(Wake Forest University), Jeffrey A. Bogart(SUNY Upstate Medical University), M. Mix(SUNY Upstate Medical University), Nathan R. Foster(University Health Network), Thomas E. Stinchcombe(Duke Medical Center), N. Razavian(Moffitt Cancer Center), Brandy L. Jaszewski(Mayo Clinic), Fran Laurie(University of Massachusetts Chan Medical School), Everett E. Vokes(University of Chicago), Gregory A. Masters(Christiana Care Health System), Ryan S. Alden(AstraZeneca (Singapore)), Xiaofei Wang(NCR (United States)), Koren Smith(University of Massachusetts Chan Medical School), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Jeffrey D. Bradley(Hospital of the University of Pennsylvania)
Cited by 11
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2016|843
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis
|International Journal of Radiation Oncology*Biology*Physics|2013|673